Cytosorbents Corporation (CTSO)
Chart Events
Performance Outlook
| Previous Close | 8.82 |
| Open | 8.79 |
| Bid | 8.52 x 900 |
| Ask | 8.89 x 800 |
| Day's Range | 8.53 - 8.90 |
| 52 Week Range | 3.60 - 11.74 |
| Volume | 280,287 |
| Avg. Volume | 277,062 |
| Market Cap | 370.447M |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings Date | Nov 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.88 |
- PR Newswire
CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.
- PR Newswire
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces the immediate appointment of James Komsa as Vice President - U.S. Sales and Marketing.
- PR Newswire
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announces that Health Canada has granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients under Interim Order (IO) ID 316575. CytoSorbents will collaborate with ebbtides medical, a specialty distributor of medical products throughout Canada, to ensure rapid and widespread availability of the therapy.
